Stock Groups

BioNTech eyes up to 17 billion euros in vaccine revenue in 2022 -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – Syringes seen in front a Biontech logo. This illustration was taken on November 10, 2020. REUTERS/Dado Ruvic

FRANKFURT: Germany’s BioNTech claimed Tuesday that the COVID-19 vaccination it developed with a partner would generate revenue of up to 17 Billion Euros (roughly $19 billion). Pfizer (NYSE:).

BioNTech stated in slides that it expected to earn 13 billion to 17 million euros this year from vaccine sales. This compares to a projected 16 billion-17 billion euro for 2021.

($1 = 0.8824 euros)

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damage arising from the use of this information, including chart data and signals to buy/sell, contained on this site. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]